BACKGROUND: Sacral neuromodulation is an effective therapy for overactive bladder, urinary retention, and fecal incontinence. Infection after sacral neurostimulation is costly and burdensome. Determining optimal perioperative management strategies to reduce the risk of infection is important to reduce this burden. OBJECTIVE: We sought to identify risk factors associated with sacral neurostimulator infection requiring explantation, to estimate the incidence of infection requiring explantation, and identify associated microbial pathogens. STUDY DESIGN: This is a multicenter retrospective case-control study of sacral neuromodulation procedures completed from Jan. 1, 20041, , through Dec. 31, 2014. We identified all sacral neuromodulation implantable pulse generator implants as well as explants due to infection at 8 participating institutions. Cases were patients who required implantable pulse generator explantation for infection during the review period. Cases were included if age !18 years old, follow-up data were available !30 days after implantable pulse generator implant, and the implant was performed at the institution performing the explant. Two controls were matched to each case. These controls were the patients who had an implantable pulse generator implanted by the same surgeon immediately preceding and immediately following the identified case who met inclusion criteria. Controls were included if age !18 years old, no infection after implantable pulse generator implant, follow-up data were available !180 days after implant, and no explant for any reason <180 days from implant. Controls may have had an explant for reasons other than infection at >180 days after implant. Fisher exact test (for categorical variables) and Student t test (for continuous variables) were used to test the strength of the association between infection and patient and surgery characteristics. Significant variables were then considered in a multivariable logistic regression model to determine risk factors independently associated with infection. RESULTS: Over a 10-year period at 8 academic institutions, 1930 sacral neuromodulator implants were performed by 17 surgeons. In all, 38 cases requiring device explant for infection and 72 corresponding controls were identified. The incidence of infection requiring explant was 1.97%. Hematoma formation (13% cases, 0% controls; P ¼ .004) and pocket depth of !3 cm (21% cases, 0% controls; P ¼ .031) were independently associated with an increased risk of infection requiring explant. On multivariable regression analysis controlling for significant variables, both hematoma formation (P ¼ .006) and pocket depth !3 cm (P ¼ .020, odds ratio 3.26; 95% confidence interval, 1.20e8.89) remained significantly associated with infection requiring explant. Of the 38 cases requiring explant, 32 had cultures collected and 24 had positive cultures. All 5 cases with a hematoma had a positive culture (100%). Of the 4 cases with a pocket depth !3 cm, 2 had positive cultures, 1 had negative cultures, and 1 had a missing culture result. The most common organism identified was methicillin-resistant Staphylococcus aureus (38%). CONCLUSION: Infection after sacral neuromodulation requiring device explant is low. The most common infectious pathogen identified was methicillin-resistant S aureus. Demographic and health characteristics did not predict risk of explant due to infection, however, having a postoperative hematoma or a deep pocket !3 cm significantly increased the risk of explant due to infection. These findings highlight the importance of meticulous hemostasis as well as ensuring the pocket depth is <3 cm at the time of device implant.
Introduction
Sacral nerve stimulation (SNS) is a Food and Drug Administrationeapproved treatment for patients with refractory overactive bladder, fecal incontinence, and nonobstructive urinary retention. Since its introduction by Medtronic (Minneapolis, MN) in 1997, >150,000 InterStim (Medtronic) devices have been implanted and the use of SNS is increasing. 1 Device implantation is performed in 2 stages, which has been previously reviewed. 2 Briefly, patients first undergo a testing phase whereby a lead is implanted into sacral foramen near the S3 nerve root. If there is a !50% improvement in preoperative symptoms, an implantable pulse generator (IPG) is then connected to a permanent lead and implanted under the skin of the lateral upper buttock.
As of January 2017, the reported hospital charge for an IPG implant totaled $17,803. 3 After a testing phase 77e90% of patients move on to IPG implant. 2, 4, 5 However, approximately 3e11% of patients with an IPG implant have an infectious complication that may require explant. [5] [6] [7] [8] Device explant is associated with significant morbidity including need for hospitalization for intravenous antibiotics, Original Research ajog.org surgical intervention to explant the device, higher cost, and decreased quality of life. 9 Additionally, the Centers for Medicare and Medicaid Services require mandatory reporting of hospitalacquired surgical site infections and implantable device infections, which subsequently impact hospital quality rating and reimbursement. 10 Infection of SNS requiring explant may be preventable. Patient risk factors associated with surgical site infection that are not modifiable include age, obesity, and immunocompromised status. However, modifiable factors that may decrease infection risk include antibiotic selection and timing, wound closure technique, and length of testing phase. 6 Most studies evaluating risk factors for infection have been at a single institution with a specific practice for perioperative management to prevent infection limiting generalizability. Additionally, as infection is uncommon, these studies have few cases limiting power to detect significant differences. The objective of this study was to identify risk factors associated with SNS explantation due to infection after placement of an IPG, to estimate the incidence of infection requiring explantation, and identify the associated microbial pathogens. This was done as a multicenter study due to the low a priori probability of explantation due to infection as well as to increase the generalizability of our findings to inform perioperative management guidelines. We chose to include only cases of infection requiring device explant as prior studies have reported on characteristics associated with infection that may be treated without explant, 11, 12 and because explant is associated with higher cost. (revision or removal of peripheral neurostimulator electrode array) and 64595 (revision or removal of peripheral or gastric neurostimulator pulse generator or receiver) were used to identify cases requiring IPG explant during the review period. Record review was performed to identify cases where the IPG explant was performed for infection. Infection was defined by the indication for explant being infection in the preoperative and/ or postoperative diagnosis of the explant procedure. All clinic, perioperative nursing notes, operative notes, and the admission summary that includes record of surgical skin preparation, chlorhexidine wipes, antibiotics, and other medications administered were reviewed to assess diagnosis of infection and risk factors for infection. To confirm we captured all patients who received chlorhexidine wipes in addition to record review, we also inquired as to each site's institutional policy about use of chlorhexidine wipes before surgery and 2 institutions routinely used it; therefore, the cases and controls from these institutions were considered as using preoperative chlorhexidine wash. Subjects may have had an IPG implant either as part of a staged implant (permanent lead followed by IPG implant) or a full implant (temporary lead followed by permanent lead with IPG implant). Cases were included if age !18 years old, follow-up data were available !30 days after IPG implant, and implant was performed at the institution performing the explant. Two controls were matched to each case. These controls were the patients who had an IPG implanted by the same surgeon immediately preceding and immediately following the previously identified case. Controls were included if !18 years old, no infection after IPG implant as verified by record review of postoperative clinic notes showing no signs or symptoms of infection and no diagnosis of infection by the physician, follow-up data were available !180 days after implant, and no explant for any reason <180 days from implant. Controls may have had an explant for reasons other than infection at >180 days after IPG implant. To determine the incidence of explantation due to infection, we identified all IPG implantation procedures and explantation procedures due to infection at each of the 8 participating institutions over the 10-year review period.
Materials and Methods
Patient demographic information including age, gender, body mass index (BMI), indication for SNS, medical Charlson comorbidity index, composite AJOG at a Glance Why was this study conducted? To improve knowledge of risk factors for explantation due to infection after sacral neuromodulation.
Key findings
The incidence of explantation due to infection is low. Explantation is associated with postoperative hematoma formation and pocket depth >3 cm.
What does this add to what is known?
Generalizable perioperative strategies that may reduce risk of explantation due to infection after sacral neuromodulation.
ajog.org GYNECOLOGY Original Research immunocompromising risk factors (diabetes, steroids, tobacco use, and AIDS), methicillin-resistant Staphylococcus aureus (MRSA) carrier status, and use of anticoagulants was recorded. Recent hemoglobin A1c was recorded for diabetic patients. Institutional and surgeon data including the presence of learners (fellows and residents), number of implants each surgeon performed within the review period, and surgeon specialty were recorded. Intraoperative data from implant procedures including number of leads and IPGs placed, days between lead and IPG implant, intraoperative intravenous antibiotic prophylaxis, use of irrigation antibiotic solution, postoperative antibiotic prophylaxis, IPG pocket depth recorded as incision depth from skin, pocket closure method, and postoperative complications including hematoma formation as diagnosed clinically after IPG implant were identified. Finally, we identified data related to the infection and explantation procedure including cultures, antibiotic use, hospitalization, timing of explant after implantation or antibiotic use, and whether or not reimplantation was performed.
Although there are no studies that specifically address explantation due to infection, Brueseke et al 11 found that the risk factor most highly associated with overall infection was immunocompromised status. The overall prevalence of immunocompromised status in their population was 25% and the overall prevalence of infection was 3%. However, the authors did not report the specific difference in the rates of infection between individuals with and without immunosuppression. Therefore, for our power analysis assuming a type I error of 5%, power level of 0.8, and 1:2 case-control ratio, we used the immunocompromised status as the exposure of interest and the aforementioned prevalence estimates to calculate the sample sizes required to detect a 2-fold increase, a 3-fold increase, and a 4-fold increase in the odds of explantation in the immunocompromised individuals and found sample sizes of 347 (119 cases, 238 controls), 297 (99 cases, 198 controls), and 81 (27 cases, 54 controls), respectively. Although we did not know the exact rate of explantation, we hypothesize that it is an uncommon event and decided to use the sample size estimation of 27 cases and 54 controls.
Fisher exact and Student t test tests were used to test the strength of the association between explant due to infection and subject and surgery characteristics for categorical and continuous variables, respectively. Significant variables were then considered in a multivariable logistic regression model to determine risk factors independently associated with infection. We chose to include only significant variables in the multivariable model to improve power due to the low incidence of infection requiring explantation. Statistical analysis was completed with software (STATA, Version 14; StataCorp, College Station, TX). Statistical significance was defined at the 5% significance level.
Results
A total of 1930 IPG implant procedures and 38 cases of infection requiring IPG explant were performed by 17 surgeons across a 10-year review period at 8 Fellows' Pelvic Research Network sites. The incidence of infection requiring IPG explant was 1.97%. From these implanted patients, 72 matched controls to the 38 cases were identified resulting in a total sample size of 110. Four cases had overlapping controls serving both as the preceding and following implant or cases with no other nearest implant to serve as an alternative control. The most common reported signs of infection were pain (87%), erythema (79%), induration (63%) and purulent drainage (50%); fever (2%) and sepsis (1%) were uncommon. Of the 38 cases requiring explant, 32 had cultures collected and 24 had positive cultures. All cases with a hematoma had a positive culture (100%). Of the 4 cases with a pocket depth !3 cm, 2 cases' cultures were positive, 1 case was negative, and 1 case was missing the culture result. The most common organisms identified were MRSA (38%) and methicillin-sensitive S aureus (33%) followed by Pseudomonas (10%), S epidermidis (10%), Proteus (5%), and Corynebacterium (5%). Treatment for infection prior to explantation included outpatient antibiotics (89%) and admission with intravenous antibiotics (18%). The median time between implant of IPG and explant for infection was 53 days (interquartile range [IQR] 21e150). For cases with an antibiotic trial prior to explant (n ¼ 33, 89%), the time to explant was on average 14 days after the trial of antibiotics (IQR 5e30). Reimplantation was performed in 42% of cases a median of 93 days after explant (IQR 60e365). Seven controls (9.7%) had a device explantation performed at >180 days after implant for indications of ineffective (n ¼ 5), pain (n ¼ 1), patient desired (n ¼ 1); none were considered to have an infection prior to or at the time of device removal.
All surgical procedures were performed at teaching institutions with residents and/or fellows participating in surgery. Subject demographics are summarized in Table 1 . There were no significant differences in gender, race, BMI, age, medical Charlson comorbidity index, or indication for implantation between cases and controls (Table 1) . Composite immunocompromised status was not significantly associated with explantation due to infection (59% cases, 53% controls, P ¼ .547). Of the 8 cases (21%) and 18 controls (25%) with diabetes, there was no difference in median A1c (cases 7.2, IQR 6.2e8.7; controls 7, IQR 5.7e7.1; P ¼ .675). MRSA carrier status was not associated with infection requiring explant (6% cases, 0% controls; P ¼ .118. Median surgeon volume during the 10-year review period was 235 implants (IQR 71e278). Surgeon specialty was not associated with infection requiring explant (P ¼ .955) ( Table 1) . Temporary lead-testing phases were performed in 3 cases and 6 controls and were not associated with infection requiring explant (P ¼ 1.00).
At stage I, there was no association between skin preparation solution; intraoperative, postoperative, or irrigation antibiotic; number of leads; side of lead vs pocket; or infection of leads before IPG implant and risk of explant due to infection (Table 2) . Two cases Original Research GYNECOLOGY ajog.org were diagnosed with a lead infection after stage I, which were treated with lead explant and outpatient antibiotics. These cases went on to have a full implant (lead þ IPG) after the infection was considered resolved. Both cases ultimately required explant of the IPG due to infection.
The median time between stage I and IPG implant was 14 days for both cases and controls (IQR 11e14 and 12e14, respectively) ( Table 3) . At the time of IPG implant, infection requiring explant was not associated with removal and/or placement of leads, side (Table 3) . Few patients used chlorhexidine wipes the night before surgery (8% cases, 10% controls). Suture material to close the pocket was not associated with infection (P ¼ .874). Pocket depth !3 cm was significantly associated with infection requiring explantation (21% cases, 0% controls; P ¼ .031), though IPG pocket depth was only recorded in 50% of cases and 44% of controls. There was no association between BMI and pocket depth (P ¼ .728) with obesity being present in 75% of subjects with pocket depth !3 cm, 50% of subjects with pocket depth 2e3 cm, and 58% of subjects with pocket depth 1e2 cm. There was also a significant association between infection requiring explant and postprocedural hematoma (P ¼ .004), which was identified in 5 cases (13%) and no controls, one of which required surgical drainage. No patients who developed a hematoma used chronic anticoagulation. One patient with a deep pocket also developed a postprocedural hematoma, 3 were in pockets 1e2 cm and 1 had an unrecorded pocket depth. On multivariable regression analysis controlling for hematoma and pocket depth, both hematoma formation (P ¼ .006) and pocket depth !3 cm (P ¼ .020, odds ratio 3.26; 95% confidence interval, 1.20e8.89) remained significantly 
Comment
We found a low rate of infection requiring explant of SNS of 1.97% with MRSA being the most common organism. Interestingly, a pocket depth !3 cm and hematoma formation were independently associated with infection requiring explant, which has not been reported in other studies. We found no statistically significant difference in risk of infection requiring explant based on other health or surgery characteristics. Our low rate of infection and infecting organisms are consistent with other studies. 11, 13, 14 We would expect our rate to be lower than other studies as we included only cases of infection requiring explant and excluded infection treated successfully with antibiotics.
11,12
BMI or immunocompromised status as was reported by Brueseke et al 11 was not significantly associated with a risk of explantation due to infection as both the explantation group (cases) and the nonexplantation group (controls) had similarly high rates of these patients.
We found no difference in risk of infection requiring explant based on length of testing phase; this may be because most patients had a testing period of <14 days and >14-day testing period was a risk factor for infection in other studies. 15 Though infection after the testing phase before IPG implant was not significantly associated with infection requiring explant, this is likely because there were too few cases to detect a difference and the only 2 cases with such an infection both required IPG explant due to infection. Too few patients had a known MRSA carrier status to detect any association between MRSA status and infection, though MRSA was the most common organism identified.
Both pocket depth !3 cm and hematoma formation were independent risk factors for infection requiring explant. It was unexpected that a deeper pocket would be associated with an increased risk of infection as theoretically a more a superficial pocket would be at greater risk of device exposure and subsequent infection. It is possible that a deeper pocket leads to a larger potential space for fluid accumulation resulting in subsequent seroma formation, infection, and wound separation. 16 There was not association between pocket depth and BMI, though the low number of cases with a deep pocket limits the power to detect a difference. Additionally, pocket depth was only recorded in 50% of cases and controls. It is not surprising that wound hematomas were associated with infection requiring explant as in addition to blood being an excellent environment for bacterial growth, the pressure of the hematoma against the wound can reduces tissue oxygenation and delay wound healing. 17 These findings support the importance of meticulous hemostasis at the time of IPG pocket formation as well as making the IPG pocket <3 cm.
In regards to antibiotic use, the Infectious Diseases Society of America (ISDA) recommends prophylaxis with cefazolin AE aminoglycoside, cefazolin AE aztreonam, or ampicillinesulbactam; alternative prophylaxis for allergies includes clindamycin AE aminoglycoside, aztreonam, vancomycin AE aminoglycoside, or aztreonam. 18 We found no difference in risk of infection based on choice of antibiotic at implant with >50% of cases and controls having cefazolin-only antibiotic prophylaxis. This is in contrast to a study by Haraway et al 14 who found a 7-times higher odds of infection with cefazolin-only prophylaxis as compared to vancomycin prophylaxis in a review of 136 implants and 8 infection cases. There are insufficient data to support the use of postoperative oral antibiotic prophylaxis, nor is it recommended by the device manufacturer, yet 80% of high-volume providers use postoperative antibiotics to prevent surgical site infection. 19 With high rates of postoperative antibiotic prophylaxis (68% cases, 60% controls) and antibiotic irrigation solution (68% cases, 71% controls) at the time of implant, we found no significant association between antibiotic prophylaxis and infection requiring explant. Given the high use in our study, in an era of multidrug-resistant bacteria, further studies are necessary to validate the benefit of these prophylaxis measures.
The primary limitations of our study include the uncommon event of explant due to infection limiting power to detect significant differences for the variables of interest. We did not record use of intraoperative anticoagulant prophylaxis as given the short procedure time it seemed unlikely to be used at most institutions, but this would be a consideration for future evaluation given the association of hematoma and infection. Additionally, it is possible there were missed cases of asymptomatic postoperative hematomas after IPG implant in control subjects. An additional limitation of our study was that only 50% of patients had pocket depth recorded in the operative note, which limits the generalizability of our findings. We did not assess operating time for stage I or stage II procedures and cannot assess the risk of length of surgery on infection rate in this study, which was noted to be a risk factor for infection by Guralnick et al. 13 Due to low use in our study, we are unable to determine if use of a gentamicin-impregnated collagen sheet or chlorhexidine wash prior to surgery would reduce the risk of infection as has been seen in single-institution retrospective chart reviews.
11, 20 We also cannot comment on the risk factors for infection treated with antibiotics as we did not include these patients in our review.
The major strengths of our study are the multicenter design to increase management, surgeon, and patient diversity and generalizability of the results. We had a large number of case subjects with sufficient immunocompromising risk factors to detect a difference, if present. Additionally, we evaluated the efficacy of various antibiotic prophylaxis regimens (intravenous, irrigation, oral postoperative) at both stages I and II to reduce the risk of infection.
Other specialties with implantable devices, specifically the American Heart Association for implantable cardiac electronic devices, have developed guidelines for the diagnosis, management, and prevention of implantable device infection. 21 We propose that a similar guideline be developed for sacral neuromodulation. Based on our findings, we would suggest the following: (1) use of either betadine or chlorhexidine for skin preparation; (2) administer intraoperative antibiotic prophylaxis in line with ISDA recommendations; (3) consider developing a pocket depth of <3 cm at the time of IPG placement; and (4) maintain meticulous hemostasis to avoid subsequent hematoma formation. We further recommend the preoperative use of chlorhexidine wipes based on the review by Brueseke et al 11 showing a 5.7% reduction in infection (7.4e1.7%, P ¼ .002). Based on the existing literature and our study, there is not sufficient evidence to support the routine use of intraoperative irrigation with antibiotic solution or postoperative antibiotic prophylaxis. n
